Potential dual immunomodulatory role of VEGF in ulcerative colitis and colorectal carcinoma

International Journal of Medical Sciences

Volumn 11, Issue 9, 2014, Pages 936-947

  Zdravkovic, Natasa D ^a   Jovanovic, Ivan P ^b   Radosavljevic, Gordana D ^b   Arsenijevic, Aleksandar N ^b   Zdravkovic, Nebojsa D ^b   Mitrovic, Slobodanka Lj ^b   Arsenijevic, Nebojsa N ^b  

^a CLINICAL CENTER KRAGUJEVAC   (Serbia)

^b UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Colorectal carcinoma; Th1; Th17; Ulcerative colitis; VEGF

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; PROTEIN P16; PROTEIN P53; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CYTOKINE; TP53 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER TISSUE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TH1 CELL; TH17 CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS; AGED; BIOSYNTHESIS; CARCINOGENESIS; COLORECTAL TUMOR; GENETICS; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CARCINOGENESIS; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CYTOKINES; FEMALE; HUMANS; IMMUNOMODULATION; INFLAMMATION; INTERFERON-GAMMA; MALE; MIDDLE AGED; TH1 CELLS; TH17 CELLS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903900133     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8277     Document Type: Article

References (61)

1. Matkowskyj KA, Chen ZE, Rao MS, Yang GY. Dysplastic lesions in inflammatory bowel disease. Arch Pathol Lab Med 2013; 137: 338-350.
2. Raza A, Yousaf W, Giannella R, Shata MT. Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease. Expert Rev Clin Immunol. 2012; 8: 161-8.
3. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology; Seventh edition. Elsevier. 2012: 225-243.
4. Seril DN, Liao J, West AB, Yang GJ. High-iron diet: foe or feat in ulcerative colitis and ulcerative colitis-associated carcinogenesis. J Clin Gastroenterol 2006; 40: 391-397.
5. Seril DN, Liao J, Yang GJ, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in human and animal models. Carcinogenesis 2003; 24: 353-362.
6. Yang GJ, Taboada S, Liao J. Inflammatory bowel disease: a model of chronic inflammation-induced cancer. Methods Mol Biol 2009; 511: 193-233.
7. Itzkowitz SH and Yio X. Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287: 7-17.
8. Debniak T, Gorski B, Huzarski T, Byrski T, Cybulski C, Mackiewicz A et al. A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet 2005; 42: 763-765.
9. Diehl JA, Zindy F, and Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997; 11: 957-972.
10. Cudejko C, Wouters K, Fuentes L, Hannou SA, Paquet C, Bantubungi K et al. p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages. Blood 2011; 118: 2556-2566.
11. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
12. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994; 107: 369-78.
13. Burmer GC, Rabinovitch PS, Haggitt RC, Crispin DA, Brentnall TA, Kolli VR et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 1992; 103: 1602-10.
14. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000; 60: 3333-7.
15. Willenbucher RF, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH et al. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol 1999; 154: 1825-30.
16. Brentnall TA. Molecular underpinnings of cancer in ulcerative colitis. Curr Opin Gastroenterol 2003; 19: 64-8.
17. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
18. Chong SK, Blackshaw AJ, Boyle S, Williams CB, Walker-Smith JA. Histological diagnosis of chronic inflammatory bowel disease in childhood. Gut 1985; 26: 55-9.
19. (IARC)., International Agency for Research on Cancer. Tumours of the colon and rectum. In: Hamilton SR, Aaltonen LA, editors. Pathology and genetics. Tumours of the digestive system. Lyon: IARC Press; 2000: 110-1.
20. Jovanovic I, Radosavljevic G, Mitrovic M, Lisnic Juranic V, McKenzie ANJ, Arsenijevic N et al. ST2 Deletion Enhances Innate and Acquired Immunity to Murine Mammary Carcinoma. Eur J Immunol 2011; 41: 1902-12.
21. Radosavljevic G, Ljujic B, Jovanovic I, Srzentic Z, Pavlovic S, Zdravkovic N et al. Interleukin-17 may be a valuable serum tumour marker in patients with colorectal carcinoma. Neoplasma 2010; 57: 135-44.
22. Abrahao AC, Bonelli BV, Nunes FD, Dias EP, Cabral MG. Immunohistochemical expression of p53, p16 and hTERT in oral squamous cell carcinoma and potentially malignant disorders. Braz Oral Res. 2011; 25: 34-41.
23. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99(7): 1371-85.
24. Jonathan S. Levine, and Robert Burakoff. Extraintestinal manifestations of inflammatory bowel disese. Gastroenterology and hepatlogy. 2011; 7: 235-41.
25. De Dombal FT, Watts JM, Watkinson G, Goligher JC. Local Complications of Ulcerative Colitis: Stricture, Pseudopolyposis, and Carcinoma of Colon and Rectum. British medical journal. 1966; 1: 1442-7.
26. Lashner BA, Turner BC, Bostwick DG, Frank PH, Hanauer SB. Dysplasia and cancer complicating strictures in ulcerative colitis. Digestiv disease and Sciences. 1990; 35(3): 349-352.
27. Hyun JG, Mayer L. Mechanisms underlying inflammatory bowel disease. Drug discov today dis mech 2006; 3: 457-62.
28. Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008; 126: 1620-1633.
29. Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 2004; 10: 620-625.
30. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007; 8: 967-974.
31. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70.
32. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, Mckenzie B et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-1316.
33. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004; 113: 1490-1497.
34. Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 2008; 57: 1682-1689.
35. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286.
36. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18.
37. Chidlow JH Jr, Shukla D, Grisham MB, Kevil CG. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol 2007; 293(1): G5-G18.
38. Hsu SC, Volpert OV, Steck PA, Mikkelsen T, Polverini PJ, Rao S et al. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 1996; 56: 5684-5691.
39. Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, de Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild typep 53 expression in glioblastoma cells. Nat. Genet. 1994; 8: 171-176.
40. Mukhopadhyay D, Tsiokas L and Sukhatme VP. Wild-type p53 and v-Src exertopposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995; 55: 6161-6165.
41. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD et al. Adenovirus-mediated wild-type p53 gene transferdown-regulates vascular endothelial growth factor expression and inhibits angiogenesisin human colon cancer. Cancer Res 1998; 58: 2288-2292.
42. Fontanini G, Boldrini L, Vignati S, Chine S, Basolo F, Silvestri V et al. Bcl2 and p53 regulate vascularendothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lungcarcinoma. Eur J Cancer 1998; 34: 718-723.
43. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D et al. Vascular endothelial growth factor is a predictor of relapse and stageprogression in superficial bladder cancer. Cancer Res 1997; 57: 5281-5285.
44. Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, Sakaki S et al. Restoration of Wild-Type p16 Down-Regulates Vascular Endothelial Growth FactorExpression and Inhibits Angiogenesis in Human Gliomas. Canc Res 1999; 59: 3783-3789.
45. Murakami Y, Mizoguchi F, Saito T, Miyasaka N, Kohsaka H. p16(INK4a) exerts an anti-inflammatory effect through accelerated IRAK1 degradation in macrophages. J Immunol 2012; 189: 5066-5072.
46. Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B and Iozzo RV. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Inv 1997; 100: 149-57.
47. Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 1990; 87: 7555-59.
48. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5: 893-900.
49. Iggo R, Gatter K, Bartek J, Lane D, Harris A. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-679.
50. Lang JC, Borchers J, Danahey D, Smith S, Stover DG, Agrawal A, Malone JP, Schuller DE, Weghorst CM, Holinga AJ, Lingam K, Patel CR, Esham B. Mutational status of overexpressed p16 in head and neck cancer: evidence for germline mutation of p16/p14ARF. Int J Oncol. 2002; 21: 401-8.
51. Kim YS, Hong SW, Choi JP, Shin TS, Moon HG, Choi EJ et al. Vascular endothelial growth factor is a key mediator in the development of T cell priming and its polarization to type 1 and type 17 T helper cells in the airways. J Immunol. 2009; 183: 5113-5120.
52. Basu A, Hoerning A, Datta D, Edelbauer M, Stack MP, Calzadilla K et al. Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol 2010; 184: 545-549.
53. Riddell RH, Goldman H, Ransohoff DF, Appelman H, Fenoglio C, Haggitt R et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14: 931-968.
54. Fogt F, Zhuang Z, Poremba C, Dockhorn-Dworniczak B, Vortmeyer A. Comparison of p53 immunoexpression with allelic loss of p53 in ulcerative colitis-associated dysplasia and carcinoma. Oncol Rep 1998; 5: 477-480.
55. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-539.
56. Marti LC, Pavon L, Severino P, Sibov T, Guilhen D, Moreira-Filho CA. Vascular endothelial growth factor-A enhances indoleamine 2, 3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation. Mem Inst Oswaldo Cruz 2013; 1: 1-10.
57. Nakamura I, Shibata M, Gonda K, Yazawa T, Shimura T, Anazawa T et al. Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system. Oncol Lett 2013; 5: 1682-1686.
58. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-355.
59. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Arsenijevic NN, Lukic ML. IL-33/ST2 axis in innate and acquired immunity to tumors. Oncoimmunology 2012; 1: 229-231.
60. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620-2627.
61. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002; 99: 2114-2121.